Free Trial
NASDAQ:SLRX

Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis

Salarius Pharmaceuticals logo
$0.78 +0.02 (+3.03%)
Closing price 04:00 PM Eastern
Extended Trading
$0.75 -0.03 (-3.34%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Salarius Pharmaceuticals Stock (NASDAQ:SLRX)

Key Stats

Today's Range
$0.71
$0.89
50-Day Range
$0.63
$1.20
52-Week Range
$0.45
$7.20
Volume
146,786 shs
Average Volume
1.56 million shs
Market Capitalization
$1.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Salarius Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
14th Percentile Overall Score

SLRX MarketRank™: 

Salarius Pharmaceuticals scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Salarius Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Salarius Pharmaceuticals is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Salarius Pharmaceuticals is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Salarius Pharmaceuticals has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Salarius Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.49% of the float of Salarius Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Salarius Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Salarius Pharmaceuticals has recently decreased by 34.58%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Salarius Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Salarius Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.49% of the float of Salarius Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Salarius Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Salarius Pharmaceuticals has recently decreased by 34.58%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Salarius Pharmaceuticals this week, compared to 0 articles on an average week.
  • Search Interest

    3 people have searched for SLRX on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Salarius Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Salarius Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.20% of the stock of Salarius Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 11.88% of the stock of Salarius Pharmaceuticals is held by institutions.

  • Read more about Salarius Pharmaceuticals' insider trading history.
Receive SLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SLRX Stock News Headlines

This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
Salarius Pharmaceuticals announces Langer to join SAB
See More Headlines

SLRX Stock Analysis - Frequently Asked Questions

Salarius Pharmaceuticals' stock was trading at $1.84 at the beginning of the year. Since then, SLRX stock has decreased by 59.1% and is now trading at $0.7530.

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) posted its quarterly earnings data on Wednesday, May, 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.40) by $1.37.

Salarius Pharmaceuticals shares reverse split before market open on Monday, June 17th 2024.The 1-8 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Salarius Pharmaceuticals investors own include Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Meta Platforms (META), T2 Biosystems (TTOO), NIO (NIO) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
5/14/2025
Today
7/10/2025
Next Earnings (Estimated)
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SLRX
CIK
1615219
Fax
N/A
Employees
20
Year Founded
2011

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$5.58 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.95 per share
Price / Book
0.80

Miscellaneous

Free Float
2,101,000
Market Cap
$1.61 million
Optionable
Not Optionable
Beta
0.44

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:SLRX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners